

B³ Pharma's Pipeline of Angiopep Drug Conjugates

- A Promising Lead Program and Versatile Peptide Technology Platform

Current Pipeline						
	Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3
ONCOLOGY	ANG1005: Angiopep peptide + Paclitaxel conjugate	BCBMLC*	Yellow	Yellow	Yellow	
	ANG1005: Angiopep peptide + Paclitaxel conjugate	LCBMLC**	Light Purple	Light Purple	Light Purple	
	ANG1005: Angiopep peptide + Paclitaxel conjugate	Other intracranial tumors	Light Purple	Light Purple	Light Purple	
	ANG1005: Angiopep peptide + Paclitaxel conjugate	Extracranial tumors (TNBC, liver ...)	Light Purple	Light Purple		
	ANG4043: Angiopep peptide + anti-HER2 mAb conjugate	Multiple Oncology Indications (intra- and extracranial tumors)	Grey			
	ANG1007: Angiopep peptide + Doxorubicin conjugate		Grey			
CNS	ANG2002: Angiopep peptide + Neurotensin conjugate	Pain	Grey			

* BCBMLC: Breast Cancer patients with recurrent Brain Metastases and Leptomeningeal Carcinomatosis

** LCBMLC: Lung Cancer patients with recurrent Brain Metastases and Leptomeningeal Carcinomatosis